DK0633930T3 - In vitro dannelse af humane dendritiske celler - Google Patents
In vitro dannelse af humane dendritiske cellerInfo
- Publication number
- DK0633930T3 DK0633930T3 DK93908477T DK93908477T DK0633930T3 DK 0633930 T3 DK0633930 T3 DK 0633930T3 DK 93908477 T DK93908477 T DK 93908477T DK 93908477 T DK93908477 T DK 93908477T DK 0633930 T3 DK0633930 T3 DK 0633930T3
- Authority
- DK
- Denmark
- Prior art keywords
- dendritic cells
- human dendritic
- adoptive immunotherapy
- vitro formation
- vitro
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 4
- 238000000338 in vitro Methods 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 1
- 102100039064 Interleukin-3 Human genes 0.000 abstract 1
- 108010002386 Interleukin-3 Proteins 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000016784 immunoglobulin production Effects 0.000 abstract 1
- 229940076264 interleukin-3 Drugs 0.000 abstract 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92400879A EP0563485A1 (en) | 1992-03-30 | 1992-03-30 | In vitro generation of human dendritic cells and uses thereof |
| PCT/US1993/002639 WO1993020186A1 (en) | 1992-03-30 | 1993-03-29 | In vitro generation of human dendritic cells and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0633930T3 true DK0633930T3 (da) | 2000-09-18 |
Family
ID=8211642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93908477T DK0633930T3 (da) | 1992-03-30 | 1993-03-29 | In vitro dannelse af humane dendritiske celler |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP0563485A1 (da) |
| JP (1) | JP3492361B2 (da) |
| KR (1) | KR100223395B1 (da) |
| AT (1) | ATE192189T1 (da) |
| AU (2) | AU682466B2 (da) |
| CA (1) | CA2133316C (da) |
| DE (1) | DE69328481T2 (da) |
| DK (1) | DK0633930T3 (da) |
| ES (1) | ES2145047T3 (da) |
| GR (1) | GR3033761T3 (da) |
| MX (1) | MX9301753A (da) |
| NZ (1) | NZ251585A (da) |
| PT (1) | PT633930E (da) |
| WO (1) | WO1993020186A1 (da) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2133409C (en) * | 1992-04-01 | 2011-05-24 | Ralph M. Steinman | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| DE4337396A1 (de) * | 1993-10-26 | 1995-04-27 | Beiersdorf Ag | Humane Zellinien mit Langerhans-Zell-Charakteristik |
| DE4412794A1 (de) * | 1994-04-14 | 1995-12-14 | Univ Ludwigs Albert | Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens |
| US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| US5670347A (en) | 1994-05-11 | 1997-09-23 | Amba Biosciences Llc | Peptide-mediated gene transfer |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| US5648248A (en) * | 1994-12-30 | 1997-07-15 | Boehringer Ingelheim International Gmbh | Methods for producing differentiated cells from immature hematopoietic cells |
| US6010905A (en) * | 1995-01-27 | 2000-01-04 | The United States Of America As Represented By The Department Of Health & Human Services | Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells |
| US5643786A (en) * | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
| US6340981B1 (en) | 1997-06-30 | 2002-01-22 | Sun Microsystems, Inc. | Method and apparatus for stroke substitution |
| US5871728A (en) | 1995-03-31 | 1999-02-16 | University Of Pittsburgh | Method of regulating dendritic cell maturation |
| US6121044A (en) * | 1995-07-12 | 2000-09-19 | Dendreon Corporation | Potent antigen presenting cell composition |
| US7150992B1 (en) | 1995-10-04 | 2006-12-19 | Innunex Corporation | Methods of preparing dendritic cells with flt3-ligand and antigen |
| US7361330B2 (en) | 1995-10-04 | 2008-04-22 | Immunex Corporation | Methods of using flt3-ligand in the treatment of fibrosarcoma |
| DE69734974D1 (de) * | 1996-02-08 | 2006-02-02 | Us Gov Health & Human Serv | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen |
| US6734014B1 (en) | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| US5811297A (en) * | 1996-03-07 | 1998-09-22 | Amba Biosciences, Llc | Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages |
| WO1998014561A1 (en) * | 1996-10-04 | 1998-04-09 | Becton Dickinson And Company | Identification of a cd34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues |
| EP0938548B1 (en) | 1996-11-06 | 2008-08-06 | The Regents of the University of California | Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof |
| WO1999012553A1 (en) * | 1997-09-08 | 1999-03-18 | Idec Pharmaceuticals Corporation | Methods for producing human antibodies in scid mice using dendritic cells |
| EP0922758B1 (en) | 1997-10-27 | 2009-04-15 | Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
| EP1056834A2 (en) | 1998-02-20 | 2000-12-06 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| EP1016413A1 (en) * | 1998-12-30 | 2000-07-05 | Applied Research Systems ARS Holding N.V. | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| JP2001061469A (ja) * | 1999-08-24 | 2001-03-13 | Japan Science & Technology Corp | 免疫応答誘導樹状細胞の調製方法 |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7419957B2 (en) | 2001-08-22 | 2008-09-02 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| KR100522526B1 (ko) * | 2002-11-28 | 2005-10-19 | 주식회사 바이넥스 | 면역 치료용 수지상 세포의 제조방법 |
| MXPA05012080A (es) | 2003-05-08 | 2006-02-22 | Xcyte Therapies Inc | Generacion y aislamiento de celulas t especificas al antigeno. |
| US20080145931A1 (en) | 2004-10-07 | 2008-06-19 | Argos Therapeutics, Inc. | Mature Dendritic Cell Compositions and Methods of Culturing Same |
| US7867977B2 (en) | 2005-11-03 | 2011-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Immunogenic peptides and methods of use for treating and preventing cancer |
| US7892760B2 (en) | 2007-11-19 | 2011-02-22 | Celera Corporation | Lung cancer markers, and uses thereof |
| EP2321340B1 (en) | 2008-09-02 | 2014-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel melanoma antigen peptide and uses thereof |
| US9266922B2 (en) | 2011-06-01 | 2016-02-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antigen peptide and uses thereof |
| EP2852611B1 (en) | 2012-05-22 | 2019-08-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Novel melanoma antigen peptide and uses thereof |
| ES2750367T3 (es) | 2012-05-22 | 2020-03-25 | Inst Nat Sante Rech Med | Nuevo péptido antigénico de melanoma y usos del mismo |
| US10105425B2 (en) | 2014-04-01 | 2018-10-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Isolated donor MHC-derived peptide and uses thereof |
| JP2017516752A (ja) | 2014-04-01 | 2017-06-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002531A1 (en) * | 1989-08-17 | 1991-03-07 | Peter Maccallum Cancer Institute | Method for the modulation of haemopoiesis in a mammal |
| US5128259A (en) * | 1989-10-27 | 1992-07-07 | Hahnemann University | Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation |
| US5622853A (en) * | 1990-05-01 | 1997-04-22 | Becton Dickinson And Company | T lymphocyte precursor |
-
1992
- 1992-03-30 EP EP92400879A patent/EP0563485A1/en not_active Withdrawn
-
1993
- 1993-03-29 CA CA002133316A patent/CA2133316C/en not_active Expired - Fee Related
- 1993-03-29 JP JP51751593A patent/JP3492361B2/ja not_active Expired - Fee Related
- 1993-03-29 ES ES93908477T patent/ES2145047T3/es not_active Expired - Lifetime
- 1993-03-29 NZ NZ251585A patent/NZ251585A/en unknown
- 1993-03-29 KR KR1019940703412A patent/KR100223395B1/ko not_active Expired - Fee Related
- 1993-03-29 DK DK93908477T patent/DK0633930T3/da active
- 1993-03-29 DE DE69328481T patent/DE69328481T2/de not_active Expired - Fee Related
- 1993-03-29 AT AT93908477T patent/ATE192189T1/de not_active IP Right Cessation
- 1993-03-29 MX MX9301753A patent/MX9301753A/es not_active IP Right Cessation
- 1993-03-29 AU AU39289/93A patent/AU682466B2/en not_active Ceased
- 1993-03-29 EP EP93908477A patent/EP0633930B1/en not_active Expired - Lifetime
- 1993-03-29 WO PCT/US1993/002639 patent/WO1993020186A1/en not_active Ceased
- 1993-03-29 PT PT93908477T patent/PT633930E/pt unknown
-
1997
- 1997-07-28 AU AU31558/97A patent/AU3155897A/en not_active Abandoned
-
2000
- 2000-06-23 GR GR20000401457T patent/GR3033761T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69328481D1 (de) | 2000-05-31 |
| CA2133316A1 (en) | 1993-10-14 |
| ATE192189T1 (de) | 2000-05-15 |
| EP0563485A1 (en) | 1993-10-06 |
| PT633930E (pt) | 2000-09-29 |
| JPH07505527A (ja) | 1995-06-22 |
| WO1993020186A1 (en) | 1993-10-14 |
| CA2133316C (en) | 2005-05-24 |
| AU3155897A (en) | 1997-11-20 |
| AU3928993A (en) | 1993-11-08 |
| EP0633930A1 (en) | 1995-01-18 |
| KR100223395B1 (ko) | 1999-10-15 |
| AU682466B2 (en) | 1997-10-09 |
| KR950700989A (ko) | 1995-02-20 |
| GR3033761T3 (en) | 2000-10-31 |
| DE69328481T2 (de) | 2000-09-07 |
| JP3492361B2 (ja) | 2004-02-03 |
| EP0633930B1 (en) | 2000-04-26 |
| ES2145047T3 (es) | 2000-07-01 |
| NZ251585A (en) | 1997-07-27 |
| MX9301753A (es) | 1993-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0633930T3 (da) | In vitro dannelse af humane dendritiske celler | |
| NO901986D0 (no) | Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler. | |
| DE69333433D1 (de) | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung | |
| DK66692D0 (da) | En mammal cytokin, il-11 | |
| DE69433013D1 (de) | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten | |
| DK0690127T3 (da) | Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering | |
| DK0621766T3 (da) | Hornhindeækvivalent-in-vitro-model | |
| DK0440373T3 (da) | Fremgangsmåde til aktivering af cytolytisk aktivitet af lymfocytter under anvendelse af et anti-CD28 antistof | |
| DE69332688D1 (de) | Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs | |
| DE69032816D1 (de) | Verwendung von oncostatin m zur suppression von mhc antigenen | |
| CA2118309A1 (en) | Lymphocyte Activation Antigen HB15, a Member of the Immunoglobulin Superfamily | |
| ES294161U (es) | Un articulo absorbente desechable. | |
| ATE160359T1 (de) | Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen. | |
| ATE322540T1 (de) | Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender | |
| Kooistra et al. | Killer cells of feline leukemia virus-and feline sarcoma virus-infected transformed cells: the role of NK, ADCC, and in vitro generated cytotoxic cells | |
| ES2080114T3 (es) | Procedimiento para preparar un factor inhibidor de la metastasis. | |
| TW221711B (en) | N-AFP monoclonal antibody and method of preparation thereof |